All In Biotech

NDA 220461 · Mitchell Wedling Supply

Carbon Dioxide, Usp

Carbon Dioxide · Inhalation · Radiographic Contrast Agent

Last checked: Nov 19, 2026Latest source record: Apr 21, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Apr 21, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

285

26 Phase 3, 29 recruiting

FAERS reports

115

109 serious, 14 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 5, 2026.

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 21, 2025 Original approval Letter
1 products under this application
  • CARBON DIOXIDE, USP · CARBON DIOXIDE · GAS, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Carbon Dioxide" as an intervention, any sponsor and status, largest first.

All 285 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • air embolism32
  • subcutaneous emphysema20
  • off label use16
  • post procedural complication9
  • cardiac arrest8
  • hypotension7
  • pneumoperitoneum7
  • hypercapnia6
  • drug administration error5
  • pco2 increased5
  • pneumomediastinum5
  • intestinal ischaemia4

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042
20052
20071
20091
20101
20113
20123
201312
201411
20156
201613
20175
201827
20198
20206
20211
20222
20234
20241
20254
20262

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,193 on PubMed

Sponsor: Mitchell Wedling Supply

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.